====== Glioblastoma IDH Mutant ======

No longer exist.

see [[Astrocytoma IDH-mutant]] or  [[Oligodendroglioma IDH-mutant and 1p/19q-codeleted]]
----


While [[glioblastoma]] was historically classified as [[isocitrate dehydrogenase]] (IDH)-[[wildtype]] and [[IDH]]-mutant groups, the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy ([[cIMPACT-NOW]]) and the [[World Health Organization Classification of Tumors of the Central Nervous System 2021]] clearly updated the [[nomenclature]] to reflect [[glioblastoma]] to be compatible with wildtype IDH status only.

===== Old literature =====

[[Isocitrate dehydrogenase]] (IDH) [[mutant]] [[glioblastoma]] (Glioblastoma), accounts for ~10% Glioblastomas, arises from lower grade [[diffuse glioma]] and preferentially appears in younger patients. 
----
[[MGMT promoter methylation]] has predictive value in [[IDH-mutant glioblastoma]], but its cutoff value should be higher than that for [[IDH-wildtype glioblastoma]]
((Chai R, Li G, Liu Y, Zhang K, Zhao Z, Wu F, Chang Y, Pang B, Li J, Li Y, Jiang T, Wang Y. Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma. Cancer Biol Med. 2021 Feb 15;18(1):272-282. doi: 10.20892/j.issn.2095-3941.2020.0179. PMID: 33628600; PMCID: PMC7877176.)).
----


Wu et al., aimed to establish a robust [[gene expression]]-based [[molecular]] [[classification]] of IDH-mutant Glioblastoma. A total of 33 samples from the [[Chinese Glioma Genome Atlas]] RNA-sequencing data were selected as training set, and 21 cases from Chinese Glioma Genome Atlas microarray data were used as validation set. Consensus clustering identified three groups with distinguished prognostic and molecular features. G1 group, with a poorer clinical outcome, mainly contained [[TERT]] promoter wild-type and male cases. G2 and G3 groups had better prognosis differed in gender. [[Gene ontology]] analysis showed that genes enriched in G1 group were involved in DNA replication, cell division and cycle. On the basis of the differential genes between G1 and G2/G3 groups, a six-gene signature was developed with a Cox proportional hazards model. Kaplan-Meier analysis found that the acquired signature could differentiate the outcome of low- and high-risk cases. Moreover, the signature could also serve as an independent prognostic factor for IDH-mutant Glioblastoma in the multivariate Cox regression analysis. Gene ontology and gene set enrichment analyses revealed that gene sets correlated with high-risk group were involved in cell cycle, cell proliferation, DNA replication and repair. These finding highlights heterogeneity within IDH-mutant Glioblastomas and will advance our molecular understanding of this lethal cancer
((Wu F, Chai RC, Wang Z, Liu YQ, Zhao Z, Li GZ, Jiang HY. Molecular
classification of IDH-mutant glioblastomas based on gene expression profiles.
Carcinogenesis. 2019 Feb 13. pii: bgz032. doi: 10.1093/carcin/bgz032. [Epub ahead
of print] PubMed PMID: 30877769.
)).